AlgaeBio Launches Algae Biomax Inc., A ‘Game-Changer’ for Agriculture

Vancouver, British Columbia--(October 19, 2011) - Algae Biosciences Corporation (TSXV: ABV) is pleased to announce that it is launching a new agribusiness subsidiary, generated by its ongoing biotechnology research and development operations.

Algae BioMax Inc., a wholly owned subsidiary of AlgaeBio, has been formed to encompass and further develop a potentially major breakthrough in the agricultural sector. Over the past two years, AlgaeBio has developed a system that efficiently delivers algae-based nutrients to crops through standard irrigation systems. Field tested over a two-year period, this process has demonstrated that it can boost crop yield and quality, reduce the need for chemical fertilizers, fuel, and herbicides, improve soil porosity and fertility, and strengthen plants against extreme weather, drought, and pests. The process has been designated the Algae BioMax™ system.

“Algae BioMax™ clearly demonstrates the cost and quality benefits of delivering nutrient-infused algae to crops,” says Robert J. Thompson, AlgaeBio’s Chairman. “Algae BioMax™ delivers bioavailable nutrients, vitamins, and trace elements, just when they’re needed, to substantially increase crop yield and quality.

“We believe this is potentially a game-changer for every farmer.”

AlgaeBio has conducted a successful extended pilot program at a large Arizona melon crop farm, in collaboration with a major international producer and distributor of fresh produce. Initial results from the Algae BioMax™ system show considerably higher yields for algae-infused crops — 38 per cent higher for cantaloupes, and 90 per cent higher for honeydew melons. Crops treated with the Algae BioMax™ system also contained more sugar, Vitamin C, and essential micronutrients.

According to cost tracking data generated from the pilot program, farmers can also realize significant savings in input costs of fertilizers, fungicides, and pesticides.

AlgaeBio has filed an international patent application for the Algae BioMax™ system, and is expanding research and development activities to further assess its benefits and market potential.

AlgaeBio’s mission is to become a global leader in microalgae research, development, and commercialization.

ABOUT ALGAE BIOSCIENCES CORPORATION: AlgaeBio is a Canadian biotechnology company that researches, develops, and manufactures ultra-pure products from micro and macro algae such as nutraceuticals, food additives, and pharmaceuticals. With access to near-perfect algae growing conditions, exclusive aquaculture access to a pristine brine water supply, and advanced proprietary technology, AlgaeBio produces superior human and animal consumable products, as well as offering advanced algae-based products and technologies for distribution into the agribusiness, biofuel, and aquaculture markets. AlgaeBio owns and operates large-scale production facilities near Holbrook, Ariz., and is listed on the TSX Venture Exchange (TSXV: ABV).

For more information:
Todd Kimberley
Director of Media Relations
Algae Biosciences
Phone: 403.815.2752
E-mail: t.kimberley@algaebio.com

Cautionary Statements

This news release contains "forward-looking statements" within the meaning of applicable securities laws, including statements relating to the expenditure of funds acquired by the Corporation in connection with the Offering. Although the Corporation believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to the Corporation. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements, including whether or not the Agent's Option is ultimately exercised. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this press release are made as of the date of this release and, except as required by applicable law, the Corporation does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The Corporation undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Corporation or its financial or operating results or (as applicable), their securities.

The Common Shares have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this release.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS.